1
Joseph Endl, Elsie M Eugui, Maria Elena Fuentes, Yvo Graus, Aran Frank Labrijn, Martin Lanzendoerfer, Paul Parren, Frank Rebers, Ralf Schumacher, Stefan Seeber, Jan Van De Winkel, Martine Van Vugt: Anti-OX40L antibodies. Roche Palo Alto, Grant D Green, March 10, 2009: US07501496 (19 worldwide citation)

This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from ...


2
Michel De Weers, Yvo Graus, Judith Oprins, Paul Parren, Jan Van De Winkel, Martine Van Vugt: Antibodies against CD38 for treatment of multiple myeloma. Genmab, Lahive & Cockfield, Jane E Remillard Esq, Jeanne M DiGiorgio Esq, November 9, 2010: US07829673 (17 worldwide citation)

Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.


3
Yvo Graus, Jacques Himber, Miranda Jansen Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Strein, Kay Gunnar Stubenrauch, Jan van de Winkel, Martine van Vugt: Anti-P-selectin antibodies. Hoffman La Roche, George W Johnston, Dennis P Tramaloni, Brian C Remy, July 21, 2009: US07563441 (12 worldwide citation)

This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suff ...


4
Joseph Endl, Elsie M Eugui, Maria Elena Fuentes, Yvo Graus, Aran Frank Labrijn, Martin Lanzendoerfer, Paul Parren, Frank Rebers, Ralf Schumacher, Stefan Seeber, Jan Van De Winkel, Martine Van Vugt: Anti-OX40L antibodies. Roche Palo Alto, Robert C Hall, January 11, 2011: US07868141 (7 worldwide citation)

This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from ...


5

6
Yvo Graus, Jacques Himber, Miranda Jansen Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Strein, Kay Gunnar Stubenrauch, Jan van de Winkel, Martine van Vugt: Nucleic acid molecules encoding anti-P-selectin antibodies. Hoffmann La Roche, George W Johnston, Dennis P Tramaloni, Brian C Remy, July 13, 2010: US07754867 (5 worldwide citation)

This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suff ...


7
David Satijn, Sandra Verploegen, Wim Bleeker, Steen Lisby, Jan Van De Winkel, Patrick Van Berkel, Paul Parren: Human antibody drug conjugates against tissue factor. GENMAB, Nelson Mullins Riley & Scarborough, Jane E Remillard Esq, Christopher L Frank, October 27, 2015: US09168314 (3 worldwide citation)

Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.


8
Yvo Graus, Jacques Himber, Miranda Jansen Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Strein, Kay Gunnar Stubenrauch, Jan van de Winkel, Martine van Vugt: Methods of inhibiting the binding of P-selectin to PSGL-1 with anti-P-selectin antibodies. Hoffmann La Roche, George W Johnston, Dennis P Tramaloni, Brian C Remy, November 2, 2010: US07824684 (3 worldwide citation)

This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suff ...


9
Jessica Teeling, Martin Glennie, Paul Parren, Arnout F Gerritsen, Sigrid Ruuls, Yvo Graus, Jan van de Winkel: Human monoclonal antibodies against CD20. Genmab, Hamilton Brook Smith & Reynolds P C, December 14, 2010: US07850962 (2 worldwide citation)

Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.


10
Sandra Verploegen, David P E Satijn, Rene Hoet, Paul Parren, Jan Van De Winkel, Vibeke Miller Breinholt, Eva Ehrnrooth, Ole Baadsgaard, Tom Vink, Willem Karel Bleeker, Mischa Houtkamp, Maroeska Oudshoorn, Rob N De Jong: Human antibodies against tissue factor and methods of use thereof. GENMAB, Nelson Mullins Riley & Scarborough, Jane E Remillard Esq, Christopher L Frank, October 6, 2015: US09150658 (2 worldwide citation)

Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.